Royalty Pharma Q1 Royalty Receipts +14% to $705M; FY2024 guidance reaffirmed

Royalty Pharma plc

2024-Q1 EPS reported $0.01 revenue$567,978,000

Portfolio Receipts of $717M, down 37% from $1,131M YoY due to $475M Biohaven milestone in Q1 2023.
Royalty Receipts grew 14% to $705M, led by Evrysdi, Trelegy, and the cystic fibrosis franchise.
Full-year 2024 Portfolio Receipts guidance reaffirmed at $2.6B–$2.7B, with Royalty Receipts growth of 5%–9%.
Announced ~$525M acquisition of royalties on Sanofi’s frexalimab (Phase 3 multiple sclerosis); $5.9B total liquidity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Royalty Pharma plc updated its first quarter of 2024 guidance (reaffirmed).

Period: first quarter of 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 9, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001193125-24-134758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.